vs

Side-by-side financial comparison of Bioceres Crop Solutions Corp. (BIOX) and Capitol Federal Financial, Inc. (CFFN). Click either name above to swap in a different company.

Bioceres Crop Solutions Corp. is the larger business by last-quarter revenue ($77.6M vs $57.7M, roughly 1.3× Capitol Federal Financial, Inc.). Capitol Federal Financial, Inc. runs the higher net margin — 34.9% vs -9.6%, a 44.5% gap on every dollar of revenue. Over the past eight quarters, Capitol Federal Financial, Inc.'s revenue compounded faster (12.1% CAGR vs -8.4%).

Bioceres Crop Solutions Corp is a global agricultural technology firm that develops and commercializes sustainable crop solutions including drought-tolerant seed traits, biofertilizers, and biopesticides. It serves farmers across South America, North America, Europe and Asia-Pacific, focusing on raising crop yields while reducing the environmental footprint of agricultural activities.

Capitol Federal Savings Bank (CapFed) is a federally chartered and insured savings bank founded in 1893 and headquartered in Topeka, Kansas. Capitol Federal has 51 locations serving both the Kansas and Missouri sides of the Kansas City metropolitan area with personal and business financial services. It is owned by holding company Capitol Federal Financial Inc. for trading on the Nasdaq.

BIOX vs CFFN — Head-to-Head

Bigger by revenue
BIOX
BIOX
1.3× larger
BIOX
$77.6M
$57.7M
CFFN
Higher net margin
CFFN
CFFN
44.5% more per $
CFFN
34.9%
-9.6%
BIOX
Faster 2-yr revenue CAGR
CFFN
CFFN
Annualised
CFFN
12.1%
-8.4%
BIOX

Income Statement — Q1 FY2026 vs Q2 FY2026

Metric
BIOX
BIOX
CFFN
CFFN
Revenue
$77.6M
$57.7M
Net Profit
$-7.4M
$20.1M
Gross Margin
46.8%
Operating Margin
9.3%
Net Margin
-9.6%
34.9%
Revenue YoY
-16.8%
Net Profit YoY
-20.2%
EPS (diluted)
$-0.12

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BIOX
BIOX
CFFN
CFFN
Q1 26
$57.7M
Q4 25
$56.8M
Q3 25
$77.6M
$54.6M
Q2 25
$50.7M
Q1 25
$60.6M
$48.8M
Q4 24
$98.8M
$46.9M
Q3 24
$93.3M
Q2 24
$45.0M
Net Profit
BIOX
BIOX
CFFN
CFFN
Q1 26
$20.1M
Q4 25
$20.3M
Q3 25
$-7.4M
$18.8M
Q2 25
$18.4M
Q1 25
$-1.6M
$15.4M
Q4 24
$605.2K
$15.4M
Q3 24
$-6.2M
Q2 24
$9.6M
Gross Margin
BIOX
BIOX
CFFN
CFFN
Q1 26
Q4 25
Q3 25
46.8%
Q2 25
Q1 25
39.4%
Q4 24
42.0%
Q3 24
40.2%
Q2 24
Operating Margin
BIOX
BIOX
CFFN
CFFN
Q1 26
Q4 25
44.4%
Q3 25
9.3%
42.2%
Q2 25
42.6%
Q1 25
1.5%
39.5%
Q4 24
14.5%
40.7%
Q3 24
2.5%
Q2 24
34.7%
Net Margin
BIOX
BIOX
CFFN
CFFN
Q1 26
34.9%
Q4 25
35.7%
Q3 25
-9.6%
34.5%
Q2 25
36.2%
Q1 25
-2.6%
31.6%
Q4 24
0.6%
32.9%
Q3 24
-6.6%
Q2 24
21.4%
EPS (diluted)
BIOX
BIOX
CFFN
CFFN
Q1 26
Q4 25
$0.16
Q3 25
$-0.12
$0.14
Q2 25
$0.14
Q1 25
$-0.02
$0.12
Q4 24
$0.00
$0.12
Q3 24
$-0.10
Q2 24
$0.07

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BIOX
BIOX
CFFN
CFFN
Cash + ST InvestmentsLiquidity on hand
$15.5M
$2.5M
Total DebtLower is stronger
Stockholders' EquityBook value
$288.3M
$1.0B
Total Assets
$734.9M
$9.8B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BIOX
BIOX
CFFN
CFFN
Q1 26
$2.5M
Q4 25
$232.6M
Q3 25
$15.5M
$252.4M
Q2 25
$175.0M
Q1 25
$38.5M
$340.4M
Q4 24
$29.2M
$170.3M
Q3 24
$32.3M
Q2 24
$317.8M
Stockholders' Equity
BIOX
BIOX
CFFN
CFFN
Q1 26
$1.0B
Q4 25
$1.0B
Q3 25
$288.3M
$1.0B
Q2 25
$1.0B
Q1 25
$345.0M
$1.0B
Q4 24
$346.3M
$1.0B
Q3 24
$346.0M
Q2 24
$1.0B
Total Assets
BIOX
BIOX
CFFN
CFFN
Q1 26
$9.8B
Q4 25
$9.8B
Q3 25
$734.9M
$9.8B
Q2 25
$9.7B
Q1 25
$798.2M
$9.7B
Q4 24
$835.2M
$9.5B
Q3 24
$827.3M
Q2 24
$9.6B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BIOX
BIOX
CFFN
CFFN
Operating Cash FlowLast quarter
$14.4M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BIOX
BIOX
CFFN
CFFN
Q1 26
Q4 25
$17.4M
Q3 25
$14.4M
$55.0M
Q2 25
$12.4M
Q1 25
$23.3M
$15.5M
Q4 24
$-5.4M
$5.6M
Q3 24
$5.2M
Q2 24
$19.1M
Free Cash Flow
BIOX
BIOX
CFFN
CFFN
Q1 26
Q4 25
$15.8M
Q3 25
$49.8M
Q2 25
$10.8M
Q1 25
$14.7M
Q4 24
$4.5M
Q3 24
Q2 24
$16.4M
FCF Margin
BIOX
BIOX
CFFN
CFFN
Q1 26
Q4 25
27.9%
Q3 25
91.3%
Q2 25
21.2%
Q1 25
30.2%
Q4 24
9.5%
Q3 24
Q2 24
36.5%
Capex Intensity
BIOX
BIOX
CFFN
CFFN
Q1 26
Q4 25
2.8%
Q3 25
9.5%
Q2 25
3.2%
Q1 25
1.5%
Q4 24
2.5%
Q3 24
Q2 24
5.9%
Cash Conversion
BIOX
BIOX
CFFN
CFFN
Q1 26
Q4 25
0.86×
Q3 25
2.93×
Q2 25
0.67×
Q1 25
1.01×
Q4 24
-8.85×
0.36×
Q3 24
Q2 24
1.98×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BIOX
BIOX

Segment breakdown not available.

CFFN
CFFN

Net Interest Income$52.3M91%
Noninterest Income$5.5M9%

Related Comparisons